With China at the forefront of global efforts to roll out COVID-19 vaccines, major Chinese vac-cine producers have lately turned in stellar performances in the stock market, with shares of lead-ing vaccine maker Sinopharm defying an overall decline to rise by the 10-percent daily limit on Wednesday.
An experimental vaccine developed by Sinopharm was 86 percent effective against the corona-virus, the United Arab Emirates (UAE) health ministry said on Wednesday, citing an interim analysis of in-country late-stage clinical trials. The UAE has officially approved and registered the vaccine, the country's state news agency reported.
The approval of the Chinese-made vaccine for general use was also a shot in the arm for other vaccine producers. For instance, Fosun Pharma finished up 2.88 percent in Shanghai on Wednes-day.
In a sign that China is firmly in a leading position to deliver vaccines for general use, Wang Junzhi, an academician and a member of the national vaccine R&D specialist group, revealed earlier in December that the nation plans to approve 600 million doses of an inactivated COVID-19 vaccine by the end of 2020.
